Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bstrongximab ADC - CureMeta

Drug Profile

Bstrongximab ADC - CureMeta

Alternative Names: Bstrongximab; Bstrongximab-MMAE; Bstrongximab-monomethyl auristatin E; CM-09

Latest Information Update: 18 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureMeta
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Podocalyxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Testicular cancer

Most Recent Events

  • 18 Sep 2023 Preclinical development for Testicular cancer is ongoing the US (CureMeta pipeline, September 2023)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Testicular-cancer in USA (Parenteral)
  • 29 May 2020 Pharmacodynamics data from preclinical trial in Testicular cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top